CC BY 2.0
Prevention of respiratory syncytial virus infection in children. Recommendations of the Polish Society of Paediatrics and the National Paediatric Consultant
1
President of the Polish Paediatric Society
2
Department of Paediatrics, Medical Centre for Postgraduate Education, Warsaw, Poland
3
Department of Paediatric Endocrinology and Diabetology, Medical University of Lublin, Lublin, Poland
4
Department of Gastroenterology and Infant Nutrition, Warsaw Medical University, Warsaw, Poland
5
Department of Paediatric Bone Marrow Transplantation, Oncology and Haematology, Medical University of Piastów Śląski, Wrocław, Poland
6
Department of Paediatrics, Endocrinology and Paediatric Diabetology, Medical University of Rzeszów, Rzeszów, Poland
7
Department of Paediatric Nephrology, Medical University of Piastów Śląski, Wroclaw, Poland
8
Department of Paediatrics, Gastroenterology, Allergology and Infant Nutrition, Medical University of Gdańsk, Gdańsk, Poland
9
Department of Paediatrics, Haematology and Oncology, A. Jurasz University Hospital No. 1, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland
10
Clinic of Paediatrics, Haematology and Paediatric Oncology, Zabrze, Silesian Medical University, Katowice, Poland
11
Department of Paediatric Allergology, Gastroenterology and Nutrition, Medical University, Łódź, Poland
12
Clinical Department of Paediatrics with Division of Allergology, Endocrinology, Neurology – Warsaw Children’s Hospital, Dziekanów Leśny, Poland
13
College of Medical Sciences, University of Rzeszów, Rzeszów, Poland
14
Department of Paediatrics, Oncology and Children’s Immunology, Pomeranian Medical University, Szczecin, Poland
Publication date: 2024-12-30
Pediatr Pol 2024;99(4):275-282
KEYWORDS
ABSTRACT
Respiratory syncytial virus (RSV) is one of the most important etiological agents of acute lower respiratory tract infections in children (LRTI-RSV). RSV infection occurs in almost all children during the first 2 years of life. RSV is one of the main causes of hospitalisation in the first year of life and especially in the first months of life.
In Poland, the monoclonal antibody palivizumab (Synagis) is currently available to protect infants against RSV as part of a drug programme. It is provided exclusively for premature infants and children at risk and should be administered monthly during the RSV season.
Two new methods of prophylaxis against RSV infection are currently available worldwide: a vaccine (Abrysvo, Pfizer) and a monoclonal antibody (nirsevimab, AstraZeneca and Sanofi Pasteur).
The Abrysvo vaccine is administered to mothers to give their babies protection against RSV infection. The Abrysvo vaccine is recommended for women at 32–36 weeks of pregnancy. In Poland, it is already available in pharmacies, at full price.
The monoclonal antibody nirsevimab (AstraZeneca and Sanofi Pasteur) is used in newborns and infants to protect against severe RSV infection. It is currently not available in Poland, although it is registered in Europe.
The paper presents current recommendations for the use of palivizumab (Synagis) in Poland, as well as current studies and recommendations from scientific societies and expert groups on the use of the Abrysvo vaccine and the monoclonal antibody nirsevimab (Beyfortus).
The paper also presents the rationale for the introduction of the health policy programme ”Nationwide health prevention programme: single passive immunisation with a monoclonal antibody for the prevention of lower respiratory tract infections caused by RS virus for 2025–2030”, submitted by the Polish Paediatric Society to the Ministry of Health in March 2024.
In Poland, the monoclonal antibody palivizumab (Synagis) is currently available to protect infants against RSV as part of a drug programme. It is provided exclusively for premature infants and children at risk and should be administered monthly during the RSV season.
Two new methods of prophylaxis against RSV infection are currently available worldwide: a vaccine (Abrysvo, Pfizer) and a monoclonal antibody (nirsevimab, AstraZeneca and Sanofi Pasteur).
The Abrysvo vaccine is administered to mothers to give their babies protection against RSV infection. The Abrysvo vaccine is recommended for women at 32–36 weeks of pregnancy. In Poland, it is already available in pharmacies, at full price.
The monoclonal antibody nirsevimab (AstraZeneca and Sanofi Pasteur) is used in newborns and infants to protect against severe RSV infection. It is currently not available in Poland, although it is registered in Europe.
The paper presents current recommendations for the use of palivizumab (Synagis) in Poland, as well as current studies and recommendations from scientific societies and expert groups on the use of the Abrysvo vaccine and the monoclonal antibody nirsevimab (Beyfortus).
The paper also presents the rationale for the introduction of the health policy programme ”Nationwide health prevention programme: single passive immunisation with a monoclonal antibody for the prevention of lower respiratory tract infections caused by RS virus for 2025–2030”, submitted by the Polish Paediatric Society to the Ministry of Health in March 2024.
REFERENCES (59)
1.
Li Y, Wang X, Blau DM et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet 2022; 399: 2047-2064. DOI: https://doi.org/10.1016/ S0140-6736(22)00478-0.
2.
Smith M, Kubale J, Kuan G, et al. Respiratory syncytial virus incidence and severity in a community-based prospective cohort of children aged 0-14 years. Open Forum Infect Dis 2022; 9: ofac598. DOI: 10.1093/ofid/ofac598.
3.
Martinón-Torres F, Carmo M, Platero L et al. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015-2018. BMC Infect Dis 2023; 23: 385. DOI: 10.1186/s12879-023-08358-x.
4.
Wrotek A, Kobiałka M, Jackowska T. Seasonality of respiratory syncytial virus hospitalization. In: Advances in Experimental Medicine and Biology. Springer, New York 2020; 1279, 93-100. DOI: doi.org/10.1007/5584_2020_503.
5.
Rząd M, Kanecki K, Lewtak K, et al. Human respiratory syncytial virus infections among hospitalized children in Poland during 2010-2020: study based on the National Hospital Registry. J Clin Med 2022; 11: 6451. DOI: 10.3390/jcm11216451.
6.
Order of the Minister of Health of 23 February 2023 on respiratory syncytial virus infections [Rozporządzenie Ministra Zdrowia z dnia 23 lutego 2023 r. w sprawie zakażeń wirusem syncytialnym układu oddechowego]. Dz. U. 2023 poz. 354.
7.
Department of Infectious Disease Epidemiology and Surveillance (NIZP PZH – PIB) Department of Communicable Disease Control and Border Health Protection (GIS) Incidence of selected infectious diseases in Poland from 1 January to 30 June 2024 and in the corresponding period of 2023. Available at: https://wwwold.pzh.gov.pl/oldp... (Accessed: 20.07.2024).
8.
Mazela J, Jackowska T, Czech M, et al. Epidemiology of respiratory syncytial virus hospitalizations in Poland: an analysis from 2015 to 2023 covering the entire Polish population of children aged under five years. Viruses 2024; 16: 704. DOI: https://doi.org/10.3390/v16050....
9.
Takashima MD, Grimwood K, Sly PD, et al. Epidemiology of respiratory syncytial virus in a community birth cohort of infants in the first 2 years of life. Eur J Pediatr 2021; 180: 2125-2135. DOI: 10.1007/s00431-021-03998-0.
10.
Kobiałka M, Jackowska T, Wrotek A. Risk factors for severe respiratory syncytial virus infection in hospitalized children. Viruses 2023; 15: 1713. DOI: https://doi.org/ 10.3390/v15081713.
11.
Del Riccio M, Spreeuwenberg P, Osei-Yeboah R, et al. Defining the Burden of Disease of RSV in the European Union: estimates of RSV-associated hospitalisations in children under 5 years of age. A systematic review and modelling study. J Infect Dis 2023; 228: 1528-1538. DOI: 10.1093/infdis/jiad188.
12.
Kobiałka M, Jackowska T, Wrotek A. Clinical course and complications of RSV versus non-RSV bronchiolitis in hospitalised children. Pediatr Med Rodz 2023; 19: 353-366. DOI: https://doi.org/10.15557/PiMR.....
13.
Wrotek A, Kobiałka M, Grochowski B, et al. Respiratory complications in children hospitalized with respiratory syncytial virus infection. Adv Exp Med Biol 2020; 1279: 113-120. DOI: 10.1007/5584_2020_530.
14.
Wrotek A, Czajkowska M, Jackowska T. Antibiotic treatment in patients with bronchiolitis. Adv Exp Med Biol 2019; 1211: 111-119. DOI: 10.1007/5584_2019_391.
15.
Wrotek A, Wrotek O, Jackowska T. The impact of RSV hospitalization on children’s quality of life. Diseases 2023; 11. DOI: https://doi.org/10.3390/diseas....
16.
Wrotek A, Wrotek O, Jackowska T. The estimate of parental quality of life loss due to Respiratory Syncytial Virus (RSV) hospitalization. Diseases 2023; 11. DOI: https://doi.org/10.3390/diseas....
17.
Obwieszczenie Ministra Zdrowia z dnia 17 czerwca 2024 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 lipca 2024 r. (Accessed: 20.10.2024).
20.
European Medicines Agency. First RSV vaccine to protect infants up to 6 months of age and older adults. Available at: https://www.ema.europa.eu/en/n... (Accessed: 20.10.2024).
22.
Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices – United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72: 1115-1122. DOI: http://dx.doi.org/10.15585/mmw....
23.
Maternal Respiratory Syncytial Virus Vaccination. Available at: https://www.acog.org/clinical/... (Accessed: 20.10.2024).
24.
Pregnant women are recommended to receive an RSV vaccine during pregnancy. Available at: https://immunisationhandbook.h... (Accessed: 20.10.2024).
26.
Siewert B, Małecka I, Talarek E, et al. Rekomendacje dotyczące profilaktyki biernej zakażenia syncytialnym wirusem oddechowym (RSV) w populacji niemowląt w sezonie 2024/2025. Zalecenia Polskiego Towarzystwa Wakcynologii. Pediatria po Dyplomie 2024. Available at: https://podyplomie.pl/pediatri....
27.
https://www.ema.europa.eu/pl/d... (first published: 15.11.2022; last updated: 13.12.2024) (Accessed: 15.12.2024).
29.
Beyfortus FDA Press Release. Available at: https://www.fda.gov/news-event... (Accessed: 15.10.2024).
30.
Griffin MP, Yuan Y, Takas T, et al.; Nirsevimab Study Group. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 2020; 383: 415-425. DOI: 10.1056/NEJMoa1913556.
31.
Hammitt LL, Dagan R, Yuan Y, et al.; MELODY Study Group. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 2022; 386: 837-846. DOI: 10.1056/NEJMoa2110275.
32.
Muller WJ, Madhi SA, Seoane Nuñez B, et al. Nirsevimab for prevention of RSV in term and late-preterm infants. N Engl J Med 2023; 388: 1533-1534. DOI: 10.1056/NEJMc2214773.
33.
Drysdale SB, Cathie K, Flamein F et al.; HARMONIE Study Group. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med 2023; 389: 2425-2435. DOI: 10.1056/NEJMoa2309189.
34.
Domachowske J, Madhi SA, Simões EAF. Safety of Nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med 2022; 386: 892-894. DOI: 10.1056/NEJMc2112186.
35.
Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices – United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72: 920-925. DOI: http://dx.doi.org/10.15585/mmw....
36.
O’Leary ST, Yonts AB, Gaviria-Agudelo C, et al. Summer 2023 ACIP update: RSV prevention and updated recommendations on other vaccines. Pediatrics 2023; 152: e2023063955.
37.
Athan E, Baber J, Quan K, et al., for the Study C3671006 Investigator Group. Safety and immunogenicity of bivalent RSVpreF vaccine coadministered with seasonal inactivated influenza vaccine in older adults. Clin Infect Dis 2024; 5: 1360-1368. DOI: https://doi.org/10.1093/cid/ci....
38.
Ares-Gómez S, Mallah N, Santiago-Pérez MI, et al.; NIRSE-GAL Study Group. Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study. Lancet Infect Dis 2024; 24: 817-828. DOI: https://doi.org/10.1016/ S1473-3099(24)00215-9.
39.
Coma E, Martinez-Marcos M, Hermosilla E. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care. Arch Dis Child 2024; 109: 736-741. DOI: 10.1136/archdischild-2024-327153.
40.
Ezpeleta G, Navascués A, Viguria N, et al. Effectiveness of nirsevimab immunoprophylaxis administered at birth to prevent infant hospitalisation for respiratory syncytial virus infection: a population-based cohort study. Vaccines (Basel) 2024; 12: 383. DOI: 10.3390/vaccines12040383.
41.
López-Lacort M, Muñoz-Quiles C, Mira-Iglesias A, et al. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024. Euro Surveill 2024; 29: 2400046. DOI: 10.2807/1560-7917.
42.
Calendario de inmunizaciones de la Asociación Española de Pediatría. Razones y bases de las recomendaciones 2024. https://vacunasaep.org/sites/v... (Accessed: 15.09.2024).
43.
Garcia FJA, de Arce AL, Aldean JA, et al. Immunisation schedule of the Spanish Association of Pediatrics: 2024 recommendations. An Pediatr (Engl Ed) 2024; 100: 34-45. DOI: doi.org/10.1016/j.anpedi.2023.12.001.
44.
HAS-Réponses Rapides: Nirsévimab (Beyfortus®) dans la prévention des bronchiolites à virus respiratoire syncytial (VRS) chez les nouveau-nés et les nourrissons, septembre 2023. Available at: https://www.has-sante.fr/uploa... (Accessed: 10.07.2024).
46.
Paireau J, Durand C, Raimbault S, et al. Nirsevimab effectiveness against cases of respiratory syncytial virus bronchiolitis hospitalised in paediatric intensive care units in France, September 2023-January 2024. Influenza Other Respir Viruses 2024; 18: e13311. DOI: 10.1111/irv.13311.
47.
Assad Z, Romain AS, Aupiais C, et al. Nirsevimab and hospitalization for RSV bronchiolitis. N Engl J Med 2024; 391: 144-154. DOI: 10.1056/NEJMoa2314885.
50.
Ernst C, Bejko D, Gaasch L et al. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg. Eurosurveillance 2024; 29: pii=2400033. DOI: https://doi.org/10.2807/1560-7....
51.
Consensus statement/recommendation on the prevention of respiratory syncytial virus (RSV) infections with the monoclonal antibody Nirsevimab (Beyfortus®) – 14. February 2024. Available at: https://www.sggg.ch/news/detai... (Accessed: 15.10.2024).
52.
Hodgson D, Wilkins N, van Leeuwen E, et al. Protecting infants against RSV disease: an impact and cost-effectiveness comparison of long-acting monoclonal antibodies and maternal vaccination. Lancet Reg Health Eur 2024; 38: 100829. DOI: 10.1016/j.lanepe.2023.100829.
53.
Smith CM, Sandrini S, Datta S, et al. Respiratory syncytial virus increases the virulence of Streptococcus pneumoniae by binding to penicillin binding protein 1a. A new paradigm in respiratory infection. Am J Respir Crit Care Med 2014; 190: 196-207. DOI: 10.1164/rccm.201311-2110OC.
54.
National Immunisation Advisory Committee, Royal College of Physicians in Ireland. Recommendations for passive immunisation and vaccination against Respiratory Syncytial Virus in infants, children and older adults. 12.10.2023. https://rcpi.access.preservica... (Accessed: 30.07.2024).
55.
Advisory Report of the Superior Health Council no. 9760. Preventive strategies against RSV disease in children December 6, 2023. https://www.health.belgium.be/....
56.
Immunisation against RSV in the first year of life. The Hague: Health Council of the Netherlands, 2024; publication no. 2024/03. Febuary 14, 2024.
57.
STIKO: Prophylaxe von RSV-Erkrankungen mit Nirsevimab bei Neugeborenen und Säuglingen. Epidemiologisches Bulletin 26. 2024; 27 Juni 2024.
58.
The health system burden of respiratory syncytial virus (RSV) in Europe. EHMA White Paper. https://ehma.org/app/uploads/2... (Accessed: 10.06.2024).
59.
Riccò M, Cascio A, Corrado S, et al. Impact of nirsevimab immunization on pediatric hospitalization rates: a systematic review and meta-analysis. Vaccines (Basel) 2024; 12: 640. DOI: 10.3390/vaccines12060640.
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
